MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling

William W. Du1,2,*, Ling Fang1,2,*, Minhui Li1,3,2, Xiangling Yang1,2, Yaoyun Liang4, Chun Peng1,4, Wei Qian5, Yunxia Q. O’Malley6, Ryan W. Askeland6, Sonia L. Sugg6, Jun Qian6, Jiang Lin5, Zide Jiang3, Albert J. Yee1, Michael Sefton1, Zhaoqun Deng1,2, Sze Wan Shan1,2, Chia-Hui Wang1,2 and Burton B. Yang1,2,*

1Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5, Canada
2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, M5S 1A8, Canada
3Department of Plant Pathology, South China Agricultural University, Guangzhou, China
4Departments of Biology, York University, Toronto, M3J 1P3, Canada
5The Affiliated People’s Hospital of Jiangsu University, Zhenjiang City, China
6Division of Surgical Oncology and Endocrine Surgery, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA

*These authors contributed equally

Author for correspondence (byang@sri.utoronto.ca)

Accepted 24 January 2013
Journal of Cell Science 126, 1440–1453
© 2013. Published by The Company of Biologists Ltd
doi: 10.1242/jcs.118299

Summary
MicroRNAs are known to play regulatory roles in gene expression associated with cancer development. We analyzed levels of the microRNA miR-24 in patients with breast carcinoma and found that miR-24 was higher in breast carcinoma samples than in benign breast tissues. We generated constructs expressing miR-24 and studied its functions using both in vitro and in vivo techniques. We found that the ectopic expression of miR-24 promoted breast cancer cell invasion and migration. In vivo experiments in mice indicated that the expression of miR-24 enhanced tumor growth, invasion into local tissues, metastasis to lung tissues and decreased overall mouse survival. In the miR-24-expressing cells and tumors, EGFR was highly phosphorylated, whereas expression of the phosphatases tyrosine-protein phosphatase non-receptor type 9 (PTPN9) and receptor-type tyrosine-protein phosphatase F (PTPRF) were repressed. We confirmed that miR-24 could directly target both PTPN9 and PTPRF. Consistent with this, we found that the levels of phosphorylated epidermal growth factor receptor (pEGFR) were higher whereas the levels of PTPN9 and PTPRF were lower in the patients with metastatic breast carcinoma. Ectopic expression of PTPN9 and PTPRF decreased pEGFR levels, cell invasion, migration and tumor metastasis. Furthermore, we found that MMP2, MMP11, pErk, and ADAM15 were upregulated, whereas TIMP2 was downregulated; all of which supported the roles of miR-24 in tumor invasion and metastasis. Our results suggest that miR-24 plays a key role in breast cancer invasion and metastasis. miR-24 could potentially be a target for cancer intervention.

Key words: MicroRNA, miR-24, pEGFR, Tumor invasion, Metastasis

Introduction
MicroRNAs (miRNA) are non-coding single-stranded RNA molecules with 18–24 nucleotides, which are produced from endogenous transcripts of short stem-loop structures. Through binding to the 3’-untranslated region (3’UTR) of different target mRNAs (mRNAs), microRNAs can repress the translation of the target mRNAs (Seitz et al., 2003). As a new class of regulatory molecules, miRNAs have diverse functions in cell proliferation (Shatseva et al., 2011; Viticchie et al., 2011; Yu et al., 2012), survival (Fang et al., 2012a; Ye et al., 2011), invasion (Deng et al., 2011; Luo et al., 2012; Siragam et al., 2012), cell differentiation (Goljanek-Whysall et al., 2012; Kahai et al., 2009; Rutnam and Yang, 2012b), morphogenesis (Wang et al., 2008a), tissue growth (Shan et al., 2009), angiogenesis (Fang et al., 2011; Lee et al., 2007; Smits et al., 2010; Zou et al., 2012), tumor development (Nohata et al., 2012; Volinia et al., 2006) and metastasis (Huang et al., 2008; Ma et al., 2007; Rutnam and Yang, 2012a). The largest functional group of miRNAs is the one involved in cancer development. Recent studies have shown that miR-24 can inhibit apoptosis of both cancer cells (Qin et al., 2010) and cardiomyocytes (Qian et al., 2011) and can accelerate cell proliferation (Zaidi et al., 2009). Upregulation of miR-24 has been observed in oral carcinoma (Lin et al., 2010) and is one of the most abundant miRNAs in cervical cancer (Wang et al., 2008b). It appears that miR-24 can repress expression of the tumor suppressor p16INK4a (Lal et al., 2008). Overall however, the role of miR-24 in cancer cell invasion and metastasis is still not clear.

Epidermal growth factor receptor (EGFR) is a member of the receptor tyrosine kinases. It is expressed on the cell surface mediating a variety of signals associated with cell proliferation. It has been demonstrated that altered expression of EGFR could result in cancer development (Zhang et al., 2007). Furthermore, breast cancer patients with EGFR upregulation have a less favorable prognosis than those with EGFR-negative tumors (Koletsa et al., 2010). Phosphorylation of EGFR plays a crucial role in the biological functions of EGFR (Magkou et al., 2008). Protein-tyrosine phosphatases can remove the phosphate groups...
from the phosphorylated receptor tyrosine kinases (Tonks, 2006) and antagonize their activity (Zhu et al., 2008). It has been reported that tyrosine-protein phosphatase non-receptor type 9 (PTPN9) can dephosphorylate EGFR and inhibit growth and invasion of MBA-MD-231 cells (Yuan et al., 2010). The role of other PTPs in EGFR dephosphorylation is not clear. In this study, we demonstrated that miR-24 can activate EGFR phosphorylation resulting in enhanced tumor growth, tumor local invasion and metastasis, which resulted in decreased animal survival. Consistent with this was the activation of EGFR. The activation of EGFR activity was achieved by repressing expression of two phosphatases PTPN9 and receptor-type tyrosine-protein phosphatase F (PTPRF). We confirmed that both PTPN9 and PTPRF were the targets of miR-24.

Results
Increased expression of miR-24 in human breast carcinoma
To dissect the roles of miRNA in breast cancer development, we examined miRNA levels in breast cancer tissues and normal breast tissues. RNAs isolated from the paraffin-embedded tissues were subjected to real-time PCR analysis. The assays showed that miR-24 levels were significantly higher in breast tumor tissue than in the corresponding normal breast tissue from the same patient (Fig. 1A, \( P=0.000136 \)). We also isolated RNAs from frozen tumor tissues and the surrounding normal breast tissues. Real-time PCR analysis indicated that of the 23 pair specimens obtained from 23 patients, 15 pairs of samples showed higher levels of miR-24 in the tumors than in the normal tissues, while the other eight pairs showed lower levels of miR-24 in the tumor tissues (Fig. 1B). These experiments suggested that miR-24 may play a role in cancer development.

miR-24 promoted cell invasion, migration, proliferation and cell-cell interaction
We generated a miR-24 expression construct (Fig. 1C) which was transfected into breast cancer cells, and then used cell sorting to isolate a stable pooled cell line. After confirming integration of the construct into the genome (supplementary material Fig. S1A, upper) and expression of miR-24 (supplementary material Fig. S1A, lower), we conducted cell invasion assays. Mock- and miR-24-transfected 4T1 cells were loaded onto a Transwell insert with serum-free Dulbecco’s modified Eagle’s medium (DMEM) and then incubated at 37°C for 24 hours. The invasive cells were stained and counted in six randomly selected fields under a light microscope.

Fig. 1. Expression of miR-24 enhanced breast cancer cell invasion and migration. (A) RNAs were isolated from paraffin blocks of human breast carcinoma specimens and the matched normal breast tissues and miR-24 levels were analyzed by real-time PCR. The results showed that miR-24 levels in breast cancer tissues were significantly higher than in the corresponding normal tissue (Fig. 1A, \( P=0.000136 \)). (B) RNAs were isolated from fresh human cancer specimens and the surrounding normal breast tissues for real-time PCR analysis. The levels of miR-24 in the tumor tissues were divided by that in the non-tumor tissues. (C) Structure of miR-24 expression construct containing pre-miR-24, GFP and neomycin. The bold letters indicate two restriction sites BglII and HindIII. The sequence in lower case is an artifact sequence inserted between two pre-miR-24s. (D) A cell invasion assay. Mock- and miR-24-transfected 4T1 cells were seeded onto Transwell inserts with 100 μl serum-free DMEM and then incubated at 37°C for 24 hours. *\( P<0.01 \). Error bars indicate s.d. (n=6). Expression of miR-24 promoted cell invasion. (E) Mock- and miR-24-transfected MT-1 cells (1x10⁵) were also subjected to invasion analysis. **\( P<0.01 \). Error bars indicate s.d. (n=6). (F) The mock- and miR-24-transfected MT-1 cells (4x10⁴) were seeded onto six-well dishes for a wound healing assay. The distances between the wound center and the front of the migrating cells (vertical axis) were measured for statistical analysis. **\( P<0.01 \). Error bars indicate s.d. (n=10).
microscope. We found that cells transfected with miR-24 displayed higher levels of invasion than the mock-transfected cells (Fig. 1D; supplementary material Fig. S1B). To corroborate this result, we performed the invasion assay in a human breast cancer cell line MT-1 (Fig. 1E; supplementary material Fig. S1C) and found that expression of miR-24 promoted cancer cell invasion. The invasion assay was also performed in the presence of Matrigel and we confirmed that 4T1 cells transfected with miR-24 had higher invasive capacity than the mock-transfected cells (supplementary material Fig. S1D).

Cell migration assays were performed to examine the role of miR-24. Mock- and miR-24-transfected 4T1 and MT-1 cells were cultured until 95% confluence. The monolayer of cells was wounded and the cultures were maintained in the presence of mytomycin to inhibit cell proliferation. Cell migration was photographed under a light microscope every 24 hours. The distances between the wounding center and the front of the migrating cells were measured for statistical analysis. The experiments indicated that expression of miR-24 promoted migration of MT-1 cells (Fig. 1F; supplementary material Fig. S1E) and 4T1 cells (supplementary material Fig. S1F).

We examined proliferation of 4T1 cells transfected with miR-24 or the control vector. The experiments showed that the miR-24-transfected cells had higher rates of proliferation than the vector-transfected cells (supplementary material Fig. S1G). Analysis of cell cycle progression indicated that more vector-transfected cells than miR-24-transfected cells were in the G1 phase suggesting a lower rate of proliferation of the former cells (supplementary material Fig. S1H). Consistent with this was the finding that miR-24-transfected cells formed more and larger colonies than the mock-transfected cells in the colony formation assays (supplementary material Fig. S2A). In sphere formation assays, we observed that the miR-24-transfected cells formed more and large spheres than the mock-transfected cells (supplementary material Fig. S2B). In low serum conditions, the miR-24-transfected cells showed increased adhesion and spreading relative to the mock-transfected cells (supplementary material Fig. S2C). The above characteristics of the miR-24-transfected cells were indicative of metastatic cancer cells. We thus performed drug-resistance experiments by culturing the mock- and miR-24-transfected MT-1 cells in the presence of Docetaxel, Doxorubicin and Epirubicin and found that the miR-24-transfected cells were more resistant to these drugs than the mock-transfected cells (supplementary material Fig. S2D).

To corroborate the role of miR-24 in mediating cell activities, we developed an antisense construct to suppress miR-24 function. In cell proliferation assays, we detected that transfection of the anti-miR-24 construct decreased cell proliferation after four days of culture (supplementary material Fig. S2E). We also performed invasion and migration assays in the MDA-MB-231 cells that expressed higher levels of miR-24 and found that expression of anti-miR-24 significantly decreased the invasive capacity (supplementary material Fig. S2F,G).

Expression of miR-24 enhanced breast cancer tumor growth, local invasion and metastasis
In order to confirm the function of miR-24, three transfected stable cell lines were injected into nude mice subcutaneously. After tumors formed, their sizes were measured regularly until the mice were sacrificed or up to 80 days. The experiments showed that tumors formed by the miR-24-cells (miR-24 tumors) grew faster than the tumors formed by the mock-transfected cells (mock tumors) or the anti-miR-24-transfected cells (anti-miR-24 tumors; Fig. 2A). During the assays, mice were sacrificed when the tumors reached the limit size set by the Animal Care Committee of Sunnybrook Research Institute. The survival curves demonstrated that miR-24 expression decreased survival rates (Fig. 2B).

The tumors were harvested, sectioned, subjected to Hematoxylin and Eosin (H&E) staining. In the mock tumors, a mixture of dead cells (showing nuclear condensation and fragmentation) and live cells were detected. Cell death was reduced in the miR-24 tumors but much higher in the Anti-miR-24 tumors than in the mock tumors (Fig. 2C). In the anti-miR-24 tumors, severe necrosis was detected in the center of the tumor. In addition, significant invasion was observed in the miR-24 tumors, showing the invasion of tumor cells into muscles. Tumor sections were also probed with anti-CD34 antibody to examine angiogenesis. We found that miR-24 expression increased tumor-associated vascularization, while anti-miR-24 expression inhibited vascularization (Fig. 2D).

We further performed tumor metastatic assays. Mock- and miR-24-transfected MT-1 cells were injected into NOD-SCID mice via tail vein, 15 in each group. Six weeks after the injection, three mice in the miR-24 group developed cachexia and four had lung metastasis in necropsy. Typical metastatic lesions in the lungs are shown (supplementary material Fig. S2H). DNA was isolated from lung tissues and subjected to PCR to amplify the CMV promoter to indicate metastasis of the cancer cells. Expression of miR-24 promoted metastasis (Fig. 2E). Lung sections were obtained and subjected to H&E staining. Nodules were detected indicating metastasis of the tumor cells to the lungs (Fig. 2F). The miR-24-group showed multi-focal metastasis lesions in the lungs (supplementary material Fig. S2I).

miR-24 upregulated phosphorylated EGFR activities
Since activation of EGFR is tightly associated with tumor invasion and metastasis, we analyzed levels of phosphorylated EGFR (pEGFR) and EGFR in both 4T1 and MT-1 cells and observed a dramatic induction of pEGFR levels in both cell types, while the levels of EGFR were similar, suggesting activation of the existing EGFR protein (Fig. 3A; supplementary material Fig. S3A). The cell lines expressing higher levels of miR-24 produced higher levels of pEGFR (supplementary material Fig. S3B). We further analyzed pEGFR level in the tumor sections and found that the miR-24 tumors expressed higher level of pEGFR than the mock tumors (Fig. 3B). The effect of miR-24 on pEGFR expression was confirmed by western blot analysis, which showed higher levels of pEGFR in the miR-24 tumor than in the mock tumor (Fig. 3C, left). In addition, the miR-24 tumor displayed higher levels of pErk than the mock tumor (Fig. 3C, right). Lung sections prepared from mock and miR-24 mice were also analyzed for pEGFR activity. A higher level of pEGFR activity was displayed in the miR-24 lung nodules than in the mock control (Fig. 3D). On the other hand, transfection with anti-miR-24 decreased pEGFR level (supplementary material Fig. S3C).

We employed the pEGFR inhibitor AG1478 to confirm the effect of pEGFR in mediating miR-24 functions. Mock- and miR-24-transfected MT-1 cells were treated with AG1478 followed by analysis of pEGFR levels. We detected downregulation of pEGFR levels in the presence of AG1478 compared with the untreated miR-24-cells (supplementary material Fig. S3D, left).
Fig. 2. Expression of miR-24 enhances breast cancer tumor growth, local invasion and metastasis. (A) 4T1 cells were either mock transfected, or transfected with miR-24 or anti-miR-24 and then injected subcutaneously into BALB/c mice. Expression of miR-24 enhanced tumor growth. Significant differences are indicated by asterisks. **P<0.01. Error bars indicate the s.d. (n=3). (B) When tumors reached the maximum size allowed by Animal Care Committee, mice were sacrificed. The curve of survival indicates that miR-24 expression decreased survival rate. Since there was not much difference between the mock group and the anti-miR-24 group, only one is shown. (C) The tumor sections were subjected to H&E staining. In the miR-24 tumors, a mixture of tumor cells and muscles (arrows) could be seen, suggesting invasion of the tumor cells. In the anti-miR-24 tumors, extensive cell death was detected. (D) Left: sections of the three different tumor types were probed with anti-CD34 antibody. miR-24 expression increased tumor-associated vascularization (arrows). Scale bar: 100 μm. Right: the number of blood vessels was counted in 10 randomly selected imaging fields for statistical analysis. n=10. (E) Metastasis was estimated by isolation of DNA from lung tissues that was then subjected to PCR to amplify the CMV promoter. Expression of miR-24 promoted metastasis (n=15, P=0.00908). (F) H&E staining of lungs from mice injected with the mock- and miR-24-transfected cells showed metastatic lesions in the miR-24 lungs (arrows).
In cell invasion assays, we found that treatment with AG1478 significantly decreased cell invasion in both the miR-24- and mock-transfected cells compared with the untreated controls (Fig. 3E; supplementary material Fig. S3E). In migration assays, we found that treatment with AG1478 significantly reduced the activities of cell migration in both the miR-24- and mock-transfected cells compared with the untreated controls (Fig. 3F; supplementary material Fig. S3F).
miR-24 targeted PTPN9 and PTPRF

To test how miR-24 exerted metastasis-promoting activities, we analyzed potential targets of miR-24 using the software miRBase (http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000080). There were a great number of candidates potentially targeted by miR-24. We focused on PTPN9 and PTPRF, two protein tyrosine phosphatases. The potential binding sites appeared at nucleotides 2333–2355 for PTPN9 and nucleotides 6111–6132 for PTPRF (Fig. 4A). We examined the levels of these proteins in 4T1 and MT-1 cells stably transfected with miR-24. In both cell lines, miR-24...
expression resulted in decreased levels of PTPN9 and PTPRF (Fig. 4B, left). Similar results were obtained in the miR-24 tumor (Fig. 4B, right). Consistent with this, transfection with anti-miR-24 increased PTPN9 and PTPFR levels (Fig. 4C). Treatment with AG1478 produced little effect on PTPN9 and PTPRF expression (supplementary material Fig. S3D, right).

To confirm the targeting of PTPN9 and PTPRF by miR-24, we performed luciferase activity assays. The luciferase reporter vector was engineered with a fragment of the 3’ UTR of PTPN9 or PTPRF harboring the miR-24 target site, producing two luciferase reporter constructs Luc-PTPN9 and Luc-PTPRF (supplementary material Fig. S4A). In addition, the potential target sites were mutated as shown (Fig. 4A) producing two mutant constructs Luc-PTPN9-mut and Luc-PTPRF-mut (supplementary material Fig. S4A). Breast cancer cell line 4T1 was co-transfected with miR-24 and the luciferase reporter construct Luc-PTPN9 or Luc-PTPRF-mut. The luciferase reporter vector containing an unrelated sequence served as a negative control. The presence of the miR-24 target site reduced luciferase activities, an effect that was reduced when the target site was mutated (Fig. 4D, left). As well, co-transfection with miR-24 and Luc-PTPRF displayed significantly decreased luciferase activities compared with the control, an effect that was reversed when the target site was mutated (Fig. 4D, middle). As expected, a mixture of PTPN9 and PTPFR (50% of each) produced similar results in the luciferase activity assays (Fig. 4D, right). We also conducted the luciferase activity assays in a different cell line U343 and similar results were obtained (supplementary material Fig. S4B).

Examination of the target sequences indicated that the miR-24 target sites in the 3’ UTRs of PTPN9 (supplementary material Fig. S4C) and PTPRF (supplementary material Fig. S4D) were highly conserved across different species. In all species obtained, only one nucleotide in PTPN9 and two nucleotides in PTPRF contained some deviations, while the rest were 100% homologous.

To confirm that PTPN9 and PTPRF were important in mediating the effects of miR-24 in regulating cell invasion and migration, we introduced siRNA to suppress their expression. Cell lysates prepared from MT-1 cells transfected with siRNAs against PTPN9, PTPRF or a control oligo were analyzed by western blotting to confirm appropriate RNA silencing as compared with the control (supplementary material Fig. S4E). We then analyzed EGFR expression and its activation using lysate from miR-24-transfected cells, which served as a control. Silencing of PTPN9 and PTPRF had no effect on EGFR expression but enhanced EGFR phosphorylation, reaching levels similar to those found in miR-24-transfected cells (Fig. 4E). Treatment with EGF also enhanced EGFR phosphorylation (supplementary material Fig. S4F).

MT-1 cells were treated with siRNAs against PTPN9, PTPRF, or the control oligo. The treated cells were harvested for invasion and migration assays. Silencing PTPN9 and PTPRF by treating the cells with siRNA against PTPN9 and PTPRF, respectively, promoted cell invasion (Fig. 4F; supplementary material Fig. S4G) and migration (Fig. 4G; supplementary material Fig. S4H).

Expression of pEGFR, PTPN9 and PTPRF in human breast carcinoma cell lines and patient specimens

To examine whether there was any correlation in the expression of miR-24 and its potential protein targets, we analyzed expression of pEGFR, PTPN9 and PTPRF in a number of cell lines including human breast carcinoma cells and found that expression of pEGFR was higher in the breast cancer cell lines MDA-MB468, MT-1, and MDA-MB231 than in the other cell lines tested (supplementary material Fig. S5A). Consistent with this was the lower levels of PTPN9 and PTPRF in MDA-MB468, MT-1 and MDA-MB231. Interestingly, the levels of miR-24 were also higher in these cell lines than the other cell lines (supplementary material Fig. S5B), suggesting a potential role of miR-24 in repressing PTPN9 and PTPRF expression in these cells, resulting in promotion of EGFR activity.

We then examined expression of pEGFR, PTPN9 and PTPRF in human breast carcinoma specimens. We found that expression of pEGFR was much higher in human breast carcinoma specimens than in the normal breast tissues (Fig. 5; supplementary material Fig. S5C). On the other hand, expression of PTPN9 and PTPRF was much weaker in the tumor tissues than in the normal tissue (Fig. 5A; supplementary material Fig. S5D,E). Double staining confirmed that expression of pEGFR was stronger than expression of PTPN9 and PTPRF in the tumor tissues, which was opposite to what was found in the normal tissues (supplementary material Fig. S6). The sections were probed for miR-24 expression using the miRCury LNA microRNA ISH Optimization Kit from Exiqon. We detected high levels of mir-24 expression in the cancer cells but not in the normal ductal structure of the breast (Fig. 5B).

PTPN9 and PTPRF rescued the effects of miR-24

To further confirm that PTPN9 and PTPRF played essential roles in mediating miR-24 effect, we conducted rescue experiments. The retroviral vector pBABE was engineered with the coding sequences of either PTPN9 or PTPRF (supplementary material Fig. S7A). MT-1 cells were transfected with PTPN9 combined with miR-24, PTPRF combined with miR-24, miR-24 alone or mock transfected and then analyzed by western blotting. As expected, transfection with PTPN9 and PTPRF increased their expression respectively, which resulted in decreased pEGFR levels (Fig. 6A).

Invasion assays were performed on MT-1 cells transfected with PTPN9 combined with miR-24, PTPRF combined with miR-24, miR-24 alone or the mock construct. Enhanced cell invasion induced by miR-24 expression was abolished by transfection with PTPN9 and PTPRF (Fig. 6B; supplementary material Fig. S7B). The cells were also cultured to sub-confluence before being utilized in wound healing and migration assays. Enhanced cell migration by miR-24 expression was abolished by transfection with PTPN9 and PTPRF (Fig. 6C; supplementary material Fig. S7C). Ectopic expression of PTPN9 and PTPRF also abolished the effects of miR-24 on cell proliferation (supplementary material Fig. S7D) and colony formation (supplementary material Fig. S7E). The rescue effects of PTPN9 and PTPRF were also confirmed in another breast cancer cell line 4T1. Ectopic expression of PTPN9 and PTPRF reduced activation of pEGFR (supplementary material Fig. S7F), resulting in decreased cell invasion (supplementary material Fig. S7G), cell proliferation (supplementary material Fig. S8A), migration (supplementary material Fig. S8B) and colony formation (supplementary material Fig. S8C).

The MT-1 cells stably infected with pBABE-PTPN9 and pBABE-PTPRF were subjected to metastasis assays. After being sacrificed, the mice were examined for nodules in the lung. Lung tissues were harvested for DNA isolation followed by real-time PCR analysis to quantify ectopic DNA in the lung, which is a
The experiments indicated that there were significantly higher levels of metastasis in the miR-24-treated mice than that in the mock-treated mice (Fig. 6D). Ectopic expression of PTPN9 or PTPRF decreased metastasis significantly. The tissues were also subjected to sectioning and H&E staining. We found nodules in the miR-24-treated mice but not in the mock-treated or in the PTPN9- and PTPRF-treated mice (Fig. 6E). The lung sections were immunostained for expression of PTPN9 and PTPRF to confirm metastasis of tumor cells (supplementary material Fig. S8D) and activation of pEGFR. We found that ectopic expression of PTPN9 and PTPRF abolished the increased expression of pEGFR by miR-24 (Fig. 6F).

Overexpression of miR-24 enhanced EGFR signaling and its down-stream pathways

We finally investigated the signaling pathway mediating the effects of miR-24. Cell lysates from miR-24- or mock-transfected MT-1 cell were analyzed by western blotting and probed for expression of MMP2, MMP11, ADAM15, TIMP2 and TIMP3. We detected upregulation of MMP2, MMP11 and ADAM15, but downregulation of TIMP2 in the cells (Fig. 7A). Expression of TIMP3 was not affected. To corroborate these results, we transfected MDA-MB-231 cells with anti-miR-24 and mock constructs, followed by western blot analysis of the expression of MMP2, MMP11, ADAM15, TIMP2 and TIMP3. Opposite to the above results, we detected downregulation of MMP2, MMP11 and ADAM15 but upregulation of TIMP2 in the cells (Fig. 7B).

To confirm that the up- and downregulation of these proteins was the consequence of miR-24 targeting PTPN9 and PTPRF and activation of pEGFR, we treated the mock- and miR-24-transfected MT-1 cells with 2.0 μM AG1478. Expression of the above proteins was analyzed by western blot analysis. We detected downregulation of MMP2, MMP11 and ADAM15 but upregulation of TIMP2 in the miR-24-transfected cells (supplementary material Fig. S9A). We confirmed that expression of pEGFR, MMP2, MMP11 and ADAM15 was upregulated while expression of PTPN9, PTPRF and TIMP2 was downregulated in the miR-24 tumors as compared with the mock tumors (supplementary material Fig. S9B). Upregulation of MMP2, MMP11, AMAD15 and pErk, while downregulation of TIMP2 was also detected in human breast carcinoma tissues compared with the normal duct structures in the breast (supplementary material Fig. S9C).
To understand the signaling pathway by which miR-24 functioned, we produced a figure to show how miR-24 possibly acts in breast cancer invasion and metastasis (Fig. 7C). In brief, miR-24 targeted PTPN9 and PTPRF, and downregulated expression of PTPN9 and PTPRF, which in turn activated EGFR (pEGFR). Increased pEGFR activity promoted expression of MMP2 and MMP11, which partly

Figure 6. Rescue miR-24 effects. (A) Cell lysates prepared from MT-1 cells that were mock transfected or transfected with miR-24, miR-24 and PTPN9, or miR-24 and PTPRF were analyzed for expression and activation of PTPN9, PTPRF and EGFR. Transfection with PTPN9 and PTPRF increased their expression, respectively, which resulted in a decrease in pEGFR levels. (B) Cell invasion assays were performed with cells treated as in A (1×10⁵). Enhanced cell invasion by miR-24 expression was abolished by transfection with PTPN9 and PTPRF. **P<0.01. Error bars indicate s.d. (n=8). (C) Migration assays showed that enhanced cell migration by miR-24 expression was abolished by transfection with PTPN9 and PTPRF. **P<0.01. Error bars indicate s.d. (n=10). (D) DNA was isolated from lung tissues and subjected to PCR to amplify the CMV promoter as an indicator of metastasis. The enhanced metastasis by miR-24 was inhibited by ectopic expression of PTPN9 and PTPRF. (n=10). (E) H&E-stained sections showing that ectopic expression of PTPN9 and PTPRF inhibits metastasis in the lung. (F) Lung tissues were subjected to immunostaining with pEGFR antibody. The increased pEGFR level resulting from miR-24 expression was inhibited by PTPN9 and PTPRF.
downregulated the expression of TIMP2 and upregulated the expression of ADAM15. As a consequence, increased expression of MMP2 and MMP11 enhances breast cancer cell migration, invasion and metastasis. Thus, miR-24 targets PTPN9 and PTPRF, which coordinately regulate EGFR to mediate miR-24 functions. In an accompanying paper, we demonstrate that miR-17, producing miR-17-5p and miR-17-3p, represses PTEN, GalNT7 and vimentin. These targets, although functioning in different signal pathways, can mediate miR-17 functions coordinately, leading to the development of hepatocellular carcinoma (see Shan et al., 2013 in this issue of Journal of Cell Science).

**Discussion**

Our study demonstrated that miR-24 was highly expressed in human breast carcinoma. This suggested a role of miR-24 in cancer development/progression, which was consistent with previous studies showing that miR-24 was highly expressed in patients with gastric cancer and lung cancer (Xie et al., 2011), cervical cancer (Wang et al., 2008b) and oral carcinoma (Lin et al., 2010). MiR-24 has also been reported to target p16, a tumor suppressor (Lal et al., 2008). We found that expression of miR-24 promoted tumor growth, invasion and metastasis by upregulating EGFR activity due to its suppressive effect on
PTPN9 and PTPRF, two phosphatases of EGFR. Rescue experiments expressing these phosphatases reversed the effects of miR-24 on tumor cell invasion and metastasis. Currently reported miR-24 functions include promotion of cell proliferation (Zaidi et al., 2009) and inhibition of apoptosis in cancer cells (Qin et al., 2010) and cardiomyocytes (Qian et al., 2011). This may be due to its capacity in repressing a great number of potential genes (368 candidate targets being predicted at http://picrar.mdc-berlin.de/cgi-bin/PicTar_ vertebrate.cgi?action=Search %20for%20targets%20of%20miRNA&name2=hsa-miR- 24). In addition, miR-24 has been reported to target some ‘seedless’ 3‘UTRs (Lal et al., 2009). Initially reported ten years ago (Lagos-Quintana et al., 2001), the roles of miR-24 are only starting to be recognized in a variety of cells and tissues.

To dissect the signaling pathway associated with miR-24 promotion of tumor growth, invasion and metastasis, we examined expression of a number of oncogenes and tumor suppressors and found that EGFR was strongly activated in the miR-24 expressing cells and tumors. As a cell surface receptor, EGFR transitions from an inactive state to an active state by autophosphorylation of its tyrosine residues (Swanton et al., 2008). Phosphorylation of EGFR results in activation of downstream MARK, ERK, Akt and JNK signaling pathways leading to DNA synthesis, cell proliferation and cell migration (Schmidt-Ullrich et al., 1997; Sørensen et al., 2006). Thus, phosphorylated EGFR plays important roles in tumor invasion and metastasis (Arora and Simpson, 2008; Gong et al., 2008). Over-activation of EGFR including constant activation and mutations is often associated with cancer development and progression (Lynch et al., 2004; Walker et al., 2009). Our results showing that EGFR was strongly activated upon miR-24 overexpression appeared to be a consequence of miR-24 repressing PTPN9 and PTPRF expression. Consistent with these results were the activation of Erk, ADAM15, MMP2 and MMP11 and downregulation of TIMP2 levels, which supported a role of EGFR in mediating miR-24 activities.

Since EGFR was not a target of miR-24, we reasoned that miR-24 may have targeted the endogenous inhibitors for EGFR phosphorylation such as the protein tyrosine phosphatases (PTPs). Due to their critical roles in physiology and tissue development, a great number of PTPs were expressed in various cell types, and the activity of each PTP was tightly controlled. PTPN9 is a non-receptor type 9 phosphatase in the cytoplasm, playing a role in intracellular secretory vesicle fusion (Huynh et al., 2004). PTPN9 has been reported to inhibit EGFR signaling by dephosphorylating EGFR leading to impaired growth and invasion of breast cancer cells (Yuan et al., 2010). We showed in this study that miR-24 could promote EGFR functions by repressing PTPN9 expression. Our results confirmed the function of PTPN9 in dephosphorylating EGFR as reported (Yuan et al., 2010) and added an additional layer to the regulation of PTPN9 expression, namely the regulation of PTPN9 by miR-24. This regulation appears to be significant in breast carcinoma patients who express high levels of EGFR. We found that approximately two-thirds of breast cancer patients express high levels of miR-24 and that most of the breast carcinoma specimens displayed high levels of pEGFR. Whether or not these patients expressed high levels of activated EGFR awaits further investigation. In addition, our results demonstrated that in human breast cancer cell lines, both EGFR and miR-24 were highly expressed while PTPN9 was downregulated, suggesting a possible inhibitory role of miR-24 in PTPN9 expression while promoting EGFR activity (e.g. enhanced EGFR phosphorylation).

Furthermore, we demonstrated that PTPRF was another target of miR-24. PTPRF is a receptor-type F protein tyrosine phosphatase. Although the function of PTPRF is not clear, it has been reported that PTPRF plays a role in mesenchymal stem cell self-renewal (Song and Tuan, 2006). There have been no reports on the role of PTPRF in dephosphorylating EGFR. In this study, we showed a reverse correlation between pEGFR and PTPFR levels. These results suggested that PTPRF may dephosphorylate EGFR in these cells. In clinical specimens, we also detected an inverted relationship between PTPRF and pEGFR levels, supporting a role of PTPRF in EGFR dephosphorylation. Knockdown of PTPRF increased pEGFR levels leading to enhanced cell invasion and migration. Ectopic expression of PTPRF decreased pEGFR levels, cell invasion, migration and tumor metastasis to the lung. These results directly supported the role of PTPRF in the inhibition of EGFR activities. The precise manner by which PTPRF dephosphorylates EGFR, awaits further investigation.

Materials and Methods

The monoclonal antibodies against ERK2, pERK, and the polyclonal antibodies against EGFR, pEGFR, PTPN9, PTPRF, MMP2, MMP11 and ADAM15 were obtained from Santa Cruz Biotechnology. EGF, selective EGFR inhibitor AG1478, myotoxin, and the monoclonal antibody against β-actin were used were obtained from Sigma. The polyclonal antibodies against TIMP2 and TIMP3 were obtained from Abcam. Horseradish peroxidase-conjugated goat anti-mouse IgG and horseradish peroxidase-conjugated goat anti-rabbit IgG were obtained from Bio-Rad.

Immunoblotting was performed using the ECL Western Blot detection kit. Cell proliferation assay using WST-1 and High Pure PCR Template Preparation kits were obtained from Roche Applied Science. The MT-1 cells used in this study was originally described by Naundorf and co-workers (Naundorf et al., 1992), while 4T1 cells were described by Aslakson and Miller (Aslakson and Miller, 1992).

Construct generation

Plasmid miR-24 and control plasmid were generated which have GFP and selected antibiotics marker respectively. Both plasmids contain a Bluescript backbone, a CMV promoter driving green fluorescent protein (GFP) expression and a human H1 promoter driving pre-miR-24 or a non-related sequence serving as a control. The control plasmid was the same as the miR-24 construct except the pre-miR-24 sequence was replaced with a non-related sequence (5‘-atagtcgtgatagactcctaaagagaaagaaaattag-3‘) serving as a mock control. In order to analyze the function of miR-24, the two constructs were transferred into 4T1 cells. After cell sorting through monitoring GFP signal by FACS (fluorescence activated cell sorter), transfected stable cells were obtained and used in this study.

A luciferase reporter vector (pMr-Reporter; Ambion) was used to generate the luciferase constructs. A fragment of 3‘UTR untranslated region from human PTPN9 or PTPRF was cloned by RT-PCR. Two primers, huPTPN9-SacI (5‘-cccgagctcctctcctacgaacctcctacc-3‘) and huPTPRF-SacI (5‘-atcaaacctcccc-3‘), were synthesized to clone the 3‘UTR fragment of PTPN9 or PTPRF when cloned by RT-PCR. Two primers, huPTPN9-SacI (5‘-cccccgagctcctcctagaattccactc-3‘) and huPTPN9-MluI (5‘-cccgagctcctaatcaacctc-3‘), were synthesized to clone the 3‘UTR fragment of PTPN9, while the 3‘UTR fragment of PTPRF was cloned when the primers huPTPRF-SacI (5‘- ccccgagctcctaatcctcctactc-3‘) and huPTPRF-MluI (5‘-cccgagctcctaatcctcctactc-3‘) were used. The PCR products were digested with SacI and MluI and the fragments were inserted into a SacI- and MluI-opened pMr-Reporter Luciferase vector to obtain the luciferase constructs, Luc-PTPN9 and Luc-PTPRF, respectively. Mutations of the miR-24 binding sites were also created, which was derived by PCR approach, using two primers huPTPN9-SacI-mut (5‘-cccgagctcctacctcctcctataaatcctcctactc-3‘) and huPTPRF-MluI that were digested with SacI and MluI and the fragments were inserted into a SacI- and MluI-opened pMr-Reporter Luciferase vector to obtain the luciferase controls, Luc-PTPN9 and Luc-PTPRF, respectively. Mutations of the miR-24 binding sites were also created, which was derived by PCR approach, using two primers huPTPN9-SacI-mut (5‘-cccgagctcctacctcctcctataaatcctcctactc-3‘) and huPTPRF-MluI that were digested with SacI and MluI and the fragments were inserted into a SacI- and MluI-opened pMr-Reporter Luciferase vector to obtain the luciferase controls, Luc-PTPN9 and Luc-PTPRF, respectively.
To generate PTPRF expression construct, we performed the amplification with two primers (Ptprf-For, 5'-ccccggatccagctggctgctgac-3' and Ptprf-Rev, 5'-cccggegcggctgatctgctgga-3'). This 5694-bp fragment was cloned at BamHI and SacII sites in pBS SK vector. After confirmation of the correct sequence, the fragment was obtained with the restriction enzymes KpnI and SacII from pBS vector and sub-cloned at KpnI and SacII sites in pCDNA4/myc-HisB. An EcoRI and AgeI fragment from the PTPRF-pCDNA4/myc-HisB plasmid was released and treated with Klenow enzyme to produce blunt end and sub-cloned at the SnaBI of pBabe-puro retroviral vector.

Production of stable cell lines
The plasmids pBabe-PPTPN9 and pBabe-PPTPRF were transfected into Hek293T cells to produce retroviruses. Harvested retroviruses in the culture media were mixed with 6 μg/ml of polybrene (Sigma) and added into culture dishes to infect cells. 24 hours after infection, cells were trypsinized and diluted into 96-well plates and selected with 2 μg/ml of Puromycin (Invitrogen). Individual clones were screened by western blotting with anti-Myc antibody (Sigma).

Cell proliferation assay
The method was as described previously (Deng et al., 2013).

Cell survival assay
The method was as described previously (Yang et al., 2012).

Mammosphere formation
Harvested mock- and miR-24-transfected cells were mechanically and enzymatically dissociated in 0.05% Trypsin-EDTA at 37°C for 10 minutes, followed by resuspension in serum-free DMEM/F12 medium containing 10 ng/ml bFGF, 20 ng/ml EGF, L-glutamine (1:400) and B27 supplement (1:50). Single cell suspensions were plated in 60-mm Petri dishes at 1000 cells/well. After culturing for additional 3 days, sphere cells were collected by gentle centrifugation, dissociated to single cells in 0.05% trypsin-EDTA and then cultured to generate mammospheres of the next generation.

Cell migration assays
We performed two different cell migration assays. In the wound-healing experiment, the method was performed as described (Rutnam and Yang, 2012b). The other migration assay was performed with the modified chemotactic Boyden chamber motility assays, which was performed using 24-well cell culture plates and a 3 μm cell culture insert. The lower chamber of the Transwell was filled with 600 μl of 10% fetal bovine serum (FBS)/DMEM and incubated at 37°C for 2 hours. Mock- and miR-24-transfected cells (1x10^5) in 100 μl serum-free DMEM were gently injected onto each filter insert (upper chamber) and then incubated at 37°C for 4 hours. The filter inserts were removed from the chambers, fixed with methanol for 5 minutes and stained with Harris’ Hematoxylin (105) and B27 supplement (1:50). Single cell suspensions were plated in 60-mm Petri dishes at 1000 cells/well. After culturing for additional 3 days, sphere cells were collected by gentle centrifugation, dissociated to single cells in 0.05% trypsin-EDTA and then cultured to generate mammospheres of the next generation.

Cell invasion assay
Cell invasion assay was performed with the modified chemotactic Boyden chamber invasion assays using 24-well cell culture plates and an 8 μm cell culture insert as described previously (Rutnam and Yang, 2012b). The other migration assay was performed with the modified chemotactic Boyden chamber motility assays, which was performed using 24-well cell culture plates and a 3 μm cell culture insert. The lower chamber of the Transwell was filled with 600 μl of 10% fetal bovine serum (FBS)/DMEM and incubated at 37°C for 2 hours. Mock- and miR-24-transfected cells (1x10^5) in 100 μl serum-free DMEM were gently injected onto each filter insert (upper chamber) and then incubated at 37°C for 4 hours. The filter inserts were removed from the chambers, fixed with methanol for 5 minutes and stained with Harris’ Hematoxylin (105) and B27 supplement (1:50). Single cell suspensions were plated in 60-mm Petri dishes at 1000 cells/well. After culturing for additional 3 days, sphere cells were collected by gentle centrifugation, dissociated to single cells in 0.05% trypsin-EDTA and then cultured to generate mammospheres of the next generation.

Cell migration assays
We performed two different cell migration assays. In the wound-healing experiment, the method was performed as described (Rutnam and Yang, 2012b). The other migration assay was performed with the modified chemotactic Boyden chamber motility assays, which was performed using 24-well cell culture plates and a 3 μm cell culture insert. The lower chamber of the Transwell was filled with 600 μl of 10% fetal bovine serum (FBS)/DMEM and incubated at 37°C for 2 hours. Mock- and miR-24-transfected cells (1x10^5) in 100 μl serum-free DMEM were gently injected onto each filter insert (upper chamber) and then incubated at 37°C for 4 hours. The filter inserts were removed from the chambers, fixed with methanol for 5 minutes and stained with Harris’ Hematoxylin (105) and B27 supplement (1:50). Single cell suspensions were plated in 60-mm Petri dishes at 1000 cells/well. After culturing for additional 3 days, sphere cells were collected by gentle centrifugation, dissociated to single cells in 0.05% trypsin-EDTA and then cultured to generate mammospheres of the next generation.

Cell invasion assay
Cell invasion assay was performed with the modified chemotactic Boyden chamber invasion assays using 24-well cell culture plates and an 8 μm cell culture insert as described previously (Rutnam and Yang, 2012b). The other migration assay was performed with the modified chemotactic Boyden chamber motility assays, which was performed using 24-well cell culture plates and a 3 μm cell culture insert. The lower chamber of the Transwell was filled with 600 μl of 10% fetal bovine serum (FBS)/DMEM and incubated at 37°C for 2 hours. Mock- and miR-24-transfected cells (1x10^5) in 100 μl serum-free DMEM were gently injected onto each filter insert (upper chamber) and then incubated at 37°C for 4 hours. The filter inserts were removed from the chambers, fixed with methanol for 5 minutes and stained with Harris’ Hematoxylin (105) and B27 supplement (1:50). Single cell suspensions were plated in 60-mm Petri dishes at 1000 cells/well. After culturing for additional 3 days, sphere cells were collected by gentle centrifugation, dissociated to single cells in 0.05% trypsin-EDTA and then cultured to generate mammospheres of the next generation.

Cell survival assay
The method was as described previously (Deng et al., 2013).

Western blot analysis
Western blotting was performed as described previously (LaPierre et al., 2007).

Cell cycle analysis
Mock- and miR-24-transfected cells were washed and resuspended in cold PBS and incubated in ice-cold 70% ethanol for 3 hours. The cells were then centrifuged at 1500 rpm for 10 minutes and resuspended in propidium iodide (PI) master mix (40 mg/ml PI and 100 mg/ml RNAse at PBS) at a density of 5x10^5 cells/ml and incubated at 37°C for 30 minutes before analysis with flow cytometry.

Luciferase activity assay
Luciferase activity assay was performed using a dual-luciferase reporter system developed by Promega (E1960). This method was performed as described previously (Jeyapalan et al., 2011).

Real-time PCR
This was performed as previously described (Lee et al., 2009). The primers used as real-time PCR controls were human-U6RNAi and human-U6RNA.
formation assays, data analysis and paper writing. L.F. was involved in animal dissecting analysis, directed pathological analysis and some immunostaining. M.L. helped W.D.W. to initiate the project and was involved in some tumor formation assays. X.Y. performed some immunostaining. Y.L. generated PTEN9 mutations and PTPR expression constructs, and cell lines. C.P. supervised Y.L.’s work. W.Q., Y.Q.Q., R.W.A., S.L.S., J.Q., J.L., provided patient specimens. Z.J., A.J.Y. and M.S. were aware of the experiments and involved in discussion. Z.D. performed real-time PCR. S.W.S. was involved in generating luciferase constructs. C.-H.W. was involved in generating miR-24 expression construct. B.B.Y. designed and supervised the project, analyzed the results, and wrote the paper.

Funding
This work was supported by the Canadian Institutes of Health Research [grant numbers MOP-102635 and MOP-111171 to B.B.Y. and MOP-89931 to CP], and a Career Investigator Award from the Heart and Stroke Foundation of Ontario [grant number CI 7418 to B.B.Y.].

Supplementary material available online at http://jcs.biologists.org/lookup/suppl/doi:10.1242/jcs.118299/-/DC1

References


Fig S1. Expression of miR-24 enhanced breast cancer cell invasion, migration and proliferation. (A) Upper, DNAs isolated from 4T1 cells, MT-1 cells, and tumors expressing miR-24, anti-miR-24, or mock were subjected to PCR to confirm integration of miR-24 into the genome. Lower, RNAs were isolated from mock and miR-24 transiently transfected 4T1 cells and subjected to real-time PCR to measure mature miR-24 levels. Asterisks indicate significant differences. * p<0.05. Error bars, SD (n=3). (B) Mock- and miR-24-transfected 4T1 cells (1x10^5) were loaded into the insert with 100 ml serum-free DMEM medium and then incubated at 37°C for 12 hours. The migrated cells were stained blue and were counted in 6 randomly selected fields under a light microscope. (C) Mock- and miR-24-transfected MT-1 cells (1x10^5) suspended in 100 ml serum-free medium were loaded in the transwell insert containing Matrigel and incubated at 37°C for 24 hours for cell invasion assays. Expression of miR-24 promoted invasion. (D) Mock- and miR-24-transfected 4T1 cells (1x10^5) were subject to the same invasion assays. (E) Mock- and miR-24-transfected MT-1 cultures were wounded with a 200-μl pipette tip and cultured in 10% FBS/DMEM medium with 2 μM mytomycin for cell migration assay. Expression of miR-24 promoted migration. (F) Mock- and miR-24-transfected 4T1 cultures were subject to the same migration assay. (G) 4T1 cells stably transfected with miR-24 or mock were maintained in tissue culture dishes in DMEM with 3% FBS. Cell proliferation was determined by cell counting. **, p< 0.01, n=6. Right, typical photos of proliferating cells. (H) Mock- and miR-24-transfected 4T1 cells (5x10^4) were analyzed for cell cycle progression. Fewer miR-24 cells were present in G1 phase than mock cells.
Fig S2. Expression of miR-24 enhanced colony formation, sphere formation, cell spreading, drug resistance, tumor invasion, and metastasis. (A) Mock- and miR-24-transfected MT-1 cells (10^3) were subjected to colony formation assay. The number of colonies was counted in 6 fields of views for each plate. **, p<0.01, n=6. Lower, typical photos of colonies. (B) Mock- and miR-24-transfected MT-1 cells were subjected to mammosphere formation assay. The numbers of mammospheres were counted in 6 randomly selected fields. **, p<0.01, n=6. Right, typical mammospheres after cultured in Petri dishes for 10 days. (C) 4T1 cells transfected with miR-24 or mock were maintained in tissue culture dishes in DMEM containing 3% FBS. Cell morphology was monitored with a light microscope (upper) or examined after immunostaining (lower) to detect actin filaments (red) and nuclei (blue). (D) Mock- and miR-24-transfected MT-1 cells (1x10^4 cells/well) were inoculated and cultured in 10% FBS/DMEM medium in 96-well culture dishes for 12 hours. After cell attachment, the medium was changed to 10% FBS/DMEM containing 3 µM Docetaxel, 6 µM Doxorubicin or 8 µM Epirubicin for 24 hours. The cultures were incubated with 10 µl WST-1 reagent for 4 hours. The absorbance of the samples against a background blank control was measured by a microplate reader. **, p<0.01, n=9. Expression of miR-24 led to acquired drug-resistance of the cells. Right, typical photos are shown. (E) Mock- and anti-miR-24-transfected 4T1 cells were subject to proliferation assay in DMEM supplemented with 3% FBS (n=6). (F) Mock-, miR-24-, and anti-miR-24-transfected MDA-MB-231 cells (1x10^5) were subjected to invasion assays for 48 hours. miR-24 enhanced cell invasion but anti-miR-24 inhibited it. The invasive cells were counted for statistical analysis (lower). (G) Mock-, miR-24-, and anti-miR-24-transfected MDA-MB-231 cultures were subject to migration assays. Transfection with anti-miR-24 decreased cell migration. The migration distance was measured for statistical analysis (lower). (H) Mock- and miR-24-transfected MT-1 cells (2x10^5) were injected into NOD-SCID mice via tail vein, with 15 mice in each group. Six weeks after the injection, 3 mice in the miR-24 group developed cachexia, and 4 had lung metastasis in necropsy. Typical metastatic lesions in the lungs are shown (arrows). (I) H&E staining of lungs from mock and miR-24 lung showed multi-focal metastasis lesions in the miR-24 lungs (arrows).
**Fig S3. miR-24 affect pEGFR expression and functions.**

(A) Cell lysates from mock- and miR-24-transfected 4T1 and MT-1 cells were analyzed on Western blotting for levels of pEGFR, EGFR and β-actin. Expression of miR-24 increased pEGFR levels. (A) Single cell suspensions were plated on 96 well culture dishes. After culturing for an additional 2 days, single colony cells were moved to 6-well dishes and cultured to 70 % conference. Cell lysates were prepared and subjected to Western blot analysis for pEGFR expression. Higher levels of miR-24 were associated with higher levels of pEGFR. (C) Cell lysates prepared from vector- and anti-miR-24-transfected MDA-MB-231 cells were subjected to immunoblotting probed with antibodies against pEGFR, EGFR and β-actin. (D) Left, cell lysates prepared from mock- and miR-24-transfected MT-1 cells pre-treated with 2.0 μM AG 1478 for 24 hours were subjected to immunoblotting probed with antibodies against pEGFR, EGFR and β-actin. Increased levels of pEGFR by miR-24 expression was abolished by AG1478 treatment. Right, the lysates were also subjected to Western blot analysis for expression of PTPN9 and PTPRF. Treatment with AG1478 had little effect on expression of PTPN9 and PTPRF. (E) Mock- and miR-24-transfected MT-1 cells (1x10^5) were subject to invasion assays with or without 2.0 μM AG1478 treatment for 56 hours. The increased invasion due to miR-24 expression was abolished by AG1478 treatment. (F) Mock- and miR-24-transfected MT-1 cultures were treated with or without 2.0 μM AG1478 for migration assay. Increased cell migration acquired by miR-24 expression was abolished by AG1478 treatment.
Fragments of PTPN9 and PTPRF 3'UTRs were inserted into the luciferase reporter vector pMir-Report producing constructs Luc-PTPN9 and Luc-PTPRF. Transfection with siRNAs against PTPN9 (siN9) and PTPRF (siRF) promoted migration.

Cell lysates prepared from MT-1 cells transfected with siRNAs against PTPN9 (siN9) and PTPRF (siRF) were subjected to Western blot analysis to confirm silencing of PTPN9 and PTPRF. Treatment with 20 ng/ml EGF enhanced EGFR phosphorylation, which had additive effect with PTPN9 and PTPRF silencing. MT-1 cells (4x10^5) transfected with control oligo, siN9, and siRF were subject to migration assays. Transfection with siN9 and siRF promoted cell invasion.
**Fig S5. Relationship of the expression of pEGFR, PTPN9, PTPRF, and miR-24.** (A) Cell lysates prepared from different cell lines were subjected to western blot analysis probed with anti-pEGFR, PTPN9, and PTPRF antibodies. While expression of pEGFR was high in the human breast cancer cell lines MB-468, MT-1, and MB-231, expression of PTPN9 and PTPRF was relatively low in these three cell lines. (B) Expression of miR-24 was analyzed on these cell lines with real-time PCR. The levels of miR-24 were relatively high in the three cell lines indicated above. (C) Human breast cancer tumors and normal breast tissues from The Affiliated People's Hospital of Jiangsu University were sectioned, and stained with antibody against pEGFR. Increased staining was detected in the tumor tissues. (D) Human breast cancer tumors and normal breast tissues obtained from (upper) The Affiliated People's Hospital of Jiangsu University and (lower) University of Iowa Carver College of Medicine were sectioned, and stained with antibody against PTPN9. Decreased staining was detected in the tumor tissues. (E) Human breast cancer tumors and normal breast tissues obtained from (upper) The Affiliated People's Hospital of Jiangsu University and (lower) University of Iowa Carver College of Medicine were sectioned, and stained with antibody against PTPRF. Decreased staining was detected in the tumor tissues.
Fig S6. Double staining of pEGFR with PTPN9 or PTPRF. (A) Human breast cancer tumors and normal breast tissues were sectioned, and incubated with antibody to pEGFR, and stained with ACE (Red, SK-4200). After blocking with avidin/biotin blocking kit (SP-2001), all samples were incubated with antibody to PTPN9, and then stained with DAB (Black, SK-4100). (B) The sections were also double stained with anti-pEGFR antibody (Red) and anti-PTPRF (Black) antibodies.
Fig S7. Reversed effects of PTPN9 and PTPRF on cell activities. (A) Constructs of PTPN9 and PTPRF. (B) Mock-, miR-24-, miR-24 and PTPN9-, or miR-24 and PTPRF-transfected MT-1 cells (1x10^5) were incubated at 37°C for 48 hours for invasion assays. Enhanced cell invasion by miR-24 expression was abolished by transfection with PTPN9 and PTPRF. (C) The cells (1x10^3) were also subject to migration assay. Enhanced cell migration by miR-24 expression was abolished by transfection with PTPN9 and PTPRF. (D) MT-1 cells transfected with mock, miR-24, miR-24 and PTPN9, or miR-24 and PTPRF were maintained in tissue culture dishes in DMEM containing 1.25% FBS for 1, 3, and 5 days for proliferation assay. Increased proliferation by miR-24 expression was abolished by transfection with PTPN9 and PTPRF. (*, p<0.05; **, p<0.01, n = 4). (E) Mock-, miR-24-, miR-24 and PTPN9-, or miR-24 and PTPRF-transfected MT-1 cells (1x10^3) were subject to colony formation assays. Increases in colony formation as a result of miR-24 expression was abolished by transfection with PTPN9 and PTPRF (n = 4). Typical photos are shown (lower). (F) Cell lysates prepared from 4T1 cells transfected with mock, miR-24, miR-24 and PTPN9, or miR-24 and PTPRF were subjected to Western blot analysis for expression and activation of PTPN9, PTPRF, and EGFR. Transfection with PTPN9 and PTPRF increased their expression respectively, which resulted in decrease in pEGFR levels. (G) The mock- and miR-24-transfected 4T1 cells (1x10^3) were transfected with PTPN9 and PTPRF and incubated for 48 hours for invasion assays. PTPN9 and PTPRF partially reversed the effect of miR-24 on cell invasion (n = 8). Lower, typical photos of cell invasion.
Fig S8. Reversed effects of PTPN9 and PTPRF on proliferation, migration, colony formation, and metastasis. (A) 4T1 cells transfected with mock, miR-24, or miR-24 and PTPN9, or miR-24 and PTPRF were maintained in tissue culture dishes in DMEM with 1.25% FBS for proliferation assay (n=4). (B) The mock- and miR-24-transfected 4T1 cells (1x10^5) were transfected with PTPN9 and PTPRF as indicated for cell migration assays. PTPN9 and PTPRF reversed the effect of miR-24 on cell migration (n = 10). Lower, typical photos of cell migration. (C) The mock- and miR-24-transfected 4T1 cells (1x10^5) were transfected with PTPN9 and PTPRF and subject to colony formation assays. PTPN9 and PTPRF reversed the effect of miR-24 on the formation of colonies (n = 4). Right, typical photos of colonies. (D) The mock- and miR-24 lung tissues were subject to immuno-staining with anti-PTPN9 and anti-PTPRF antibodies. Increased expression of pEGFR and decreased expression of PTPN9 and PTPRF were detected in the tumor tissues.
Fig S9. Effects of miR-24 on other signaling molecules. (A) The mock- and miR-24- transfected MT-1 cells were treated with 2.0 μM AG 1478 for 24 hours, followed by analysis on Western blot for expression of MMP2, MMP11, ADAM15, TIMP2, and TIMP3. Treatment with AG1478 down-regulated MMP2, MMP11, and ADAM15 but up-regulated TIMP2 levels in the miR-24-transfected cells. (B) The mock- and miR-24 tumor tissues were subjected to immunohistochemistry probed with antibodies against pEGFR, PTPN9, PTPRF, MMP2, MMP11, ADAM15, and TIMP2. Increased expression of pEGFR, MMP2, MMP11, and ADAM15 was detected, while decreased expression of PTPN9, PTPRF, and TIMP2 was detected in the tumor tissues. (C) Human breast carcinoma specimens were subject to immunohistochemistry probed with antibodies against MMP2, MMP11, ADAM15, pErk, and TIMP2. Increased expression of MMP2, MMP11, ADAM15, and pErk was detected, while expression of TIMP2 was decreased in the tumor tissues.
<table>
<thead>
<tr>
<th>Age</th>
<th>Breast</th>
<th>Surgery</th>
<th>Histology</th>
<th>Grades</th>
<th>Tumor size</th>
<th>Axillary lymph nodes</th>
<th>ER</th>
<th>PR</th>
<th>HER2</th>
<th>Tumor Block</th>
<th>Benign Block</th>
</tr>
</thead>
<tbody>
<tr>
<td>23075-13</td>
<td>27</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>3.4</td>
<td>Positive (1/3)</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>D5</td>
<td>D8</td>
</tr>
<tr>
<td>34638-13</td>
<td>59</td>
<td>Right Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>2</td>
<td>1.5</td>
<td>Positive (5/10)</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>A3</td>
<td>A1</td>
</tr>
<tr>
<td>28090-09</td>
<td>33</td>
<td>Right Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>1.2</td>
<td>Positive (2/11)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>B26</td>
<td></td>
</tr>
<tr>
<td>35675-09</td>
<td>83</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>1</td>
<td>1.1</td>
<td>Positive (1/5)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>E13</td>
<td></td>
</tr>
<tr>
<td>6716-10</td>
<td>70</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>2</td>
<td>6.3</td>
<td>Positive (1/2)</td>
<td>Positive</td>
<td>Negative</td>
<td>Positive</td>
<td>D10</td>
<td></td>
</tr>
<tr>
<td>38018-09</td>
<td>53</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>2</td>
<td>1.1</td>
<td>Positive (1/1)</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>I8</td>
<td></td>
</tr>
<tr>
<td>11777-11</td>
<td>57</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>2.6</td>
<td>Positive (2/4)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>A1</td>
<td>A7</td>
</tr>
<tr>
<td>33088-13</td>
<td>49</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>2.5</td>
<td>Positive (1/3)</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>G5</td>
<td></td>
</tr>
<tr>
<td>28632-08</td>
<td>58</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>4</td>
<td>Positive (5/12)</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>A4</td>
<td>A8</td>
</tr>
<tr>
<td>9013-09</td>
<td>45</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>1.4</td>
<td>Positive (1/35)</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>B26</td>
<td>E3</td>
</tr>
<tr>
<td>9223-10</td>
<td>48</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>2</td>
<td>1.1</td>
<td>Negative (0/2)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>B2</td>
<td>B4</td>
</tr>
<tr>
<td>24019-13</td>
<td>51</td>
<td>Right Mastectomy</td>
<td>Invasive ductal with mucinous</td>
<td>2</td>
<td>1.6</td>
<td>Negative (0/4)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>E7</td>
<td>E13</td>
</tr>
<tr>
<td>21822-13</td>
<td>56</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>1.1</td>
<td>Negative (0/4)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>C3</td>
<td>C7</td>
</tr>
<tr>
<td>28219-13</td>
<td>58</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>1</td>
<td>1.0</td>
<td>Negative (0/4)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>C4</td>
<td>C5</td>
</tr>
<tr>
<td>30677-13</td>
<td>59</td>
<td>Right Invasive ductal carcinoma</td>
<td>2</td>
<td>3.1</td>
<td>Negative (0/3)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>C3</td>
<td>C6</td>
<td></td>
</tr>
<tr>
<td>30727-13</td>
<td>55</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>1.9</td>
<td>Negative (0/4)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>E4</td>
<td>E8</td>
</tr>
<tr>
<td>39550-13</td>
<td>50</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>2.6</td>
<td>Negative (0/7)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>C3</td>
<td>B5</td>
</tr>
<tr>
<td>11817-11</td>
<td>80</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>2</td>
<td>2.9</td>
<td>Negative (0/2)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>A1</td>
<td>B1</td>
</tr>
<tr>
<td>12269-11</td>
<td>59</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>1</td>
<td>0.4</td>
<td>Negative (0/4)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>A18</td>
<td>A2</td>
</tr>
<tr>
<td>25438-13</td>
<td>94</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>2</td>
<td>Negative (0/7)</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>E7</td>
<td>D19</td>
</tr>
<tr>
<td>15222-13</td>
<td>61</td>
<td>Right Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>2</td>
<td>3.8</td>
<td>Positive (7/14)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>C1</td>
<td>D5</td>
</tr>
<tr>
<td>15195-13</td>
<td>65</td>
<td>Left Invasive ductal carcinoma</td>
<td>2</td>
<td>3.5</td>
<td>Positive (32/36)</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>B15</td>
<td>B22</td>
<td></td>
</tr>
<tr>
<td>21311-13</td>
<td>44</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>2</td>
<td>2.1</td>
<td>Positive (1/17)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>A2</td>
<td>A1</td>
</tr>
<tr>
<td>23893-13</td>
<td>49</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>3.9</td>
<td>Positive (1/3)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>D9</td>
<td>D12</td>
</tr>
<tr>
<td>27208-13</td>
<td>48</td>
<td>Left Invasive ductal carcinoma</td>
<td>3</td>
<td>3.4</td>
<td>Negative (0/7)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>E8</td>
<td>D4</td>
<td></td>
</tr>
<tr>
<td>27707-13</td>
<td>39</td>
<td>Right Invasive ductal carcinoma</td>
<td>3</td>
<td>0.9</td>
<td>Positive (1/5)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>B3</td>
<td>C8</td>
<td></td>
</tr>
<tr>
<td>11558-11</td>
<td>45</td>
<td>Right Invasive ductal carcinoma</td>
<td>3</td>
<td>2</td>
<td>Positive (1/11)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>A13</td>
<td>A49</td>
<td></td>
</tr>
<tr>
<td>1474-09</td>
<td>57</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>0.4</td>
<td>Positive (1/12)</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
<td>G2</td>
<td>G10</td>
</tr>
<tr>
<td>25055-08</td>
<td>60</td>
<td>Left Invasive ductal carcinoma</td>
<td>3</td>
<td>1.9</td>
<td>Positive (1/3)</td>
<td>Positive</td>
<td>Negative</td>
<td>Positive</td>
<td>B1</td>
<td>B16</td>
<td></td>
</tr>
<tr>
<td>19057-08</td>
<td>52</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>7.8</td>
<td>Positive (18/18)</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>C7</td>
<td></td>
</tr>
<tr>
<td>17862-11</td>
<td>52</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>3.5</td>
<td>Positive (1/3)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>C1</td>
<td></td>
</tr>
<tr>
<td>19378-11</td>
<td>63</td>
<td>Right Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>1</td>
<td>3.6</td>
<td>Positive (1/4)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>D12</td>
<td></td>
</tr>
<tr>
<td>29075-11</td>
<td>77</td>
<td>Left Invasive ductal carcinoma</td>
<td>4</td>
<td>4.4</td>
<td>Positive (1/12)</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>A4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31486-11</td>
<td>50</td>
<td>Left Invasive ductal carcinoma</td>
<td>3</td>
<td>4.8</td>
<td>Positive (8/19)</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>H2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35798-11</td>
<td>57</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>1.7</td>
<td>Positive (9/19)</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>H12</td>
<td></td>
</tr>
<tr>
<td>37033-11</td>
<td>48</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>2.3</td>
<td>Positive (1/2)</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>A6</td>
<td></td>
</tr>
<tr>
<td>74330-11</td>
<td>45</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>6.3</td>
<td>Positive (7/77)</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>A6</td>
<td></td>
</tr>
<tr>
<td>35722-13</td>
<td>50</td>
<td>Left Invasive ductal carcinoma</td>
<td>3</td>
<td>3.9</td>
<td>Positive (1/3)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>B3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32212-13</td>
<td>57</td>
<td>Right Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>3.5</td>
<td>Positive (7/11)</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>A4</td>
<td></td>
</tr>
<tr>
<td>35598-13</td>
<td>40</td>
<td>Left Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>5.9</td>
<td>Positive (7/11)</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>G6</td>
<td></td>
</tr>
<tr>
<td>30703-11</td>
<td>83</td>
<td>Right Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>1</td>
<td>2.5</td>
<td>Negative (0/5)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>D6</td>
<td></td>
</tr>
<tr>
<td>25800-11</td>
<td>74</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>3.6</td>
<td>Positive (0/4)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>D6</td>
<td></td>
</tr>
<tr>
<td>19287-11</td>
<td>45</td>
<td>Right Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>3</td>
<td>Negative (0/2)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>C2</td>
<td></td>
</tr>
<tr>
<td>13853-11</td>
<td>68</td>
<td>Right Lumpectomy</td>
<td>Invasive ductal carcinoma</td>
<td>2</td>
<td>2.6</td>
<td>Negative (0/5)</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>A3</td>
<td></td>
</tr>
<tr>
<td>36126-13</td>
<td>52</td>
<td>Left Mastectomy</td>
<td>Invasive ductal carcinoma</td>
<td>3</td>
<td>5.9</td>
<td>Negative (0/2)</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>G6</td>
<td></td>
</tr>
</tbody>
</table>